Table 3. Multivariable models of FAP1 (A-D) and PDGFRβ (E-H) predicting survival of NSCLC patients with high and low expression of CD8 (A, C, E and G) and CD3 (B D, F and H, Cox regression analysis).
| (A) CD8 High | (B) CD3 High | (C) CD8 Low | (D) CD3 Low | |||||
|
HR (95% CI) |
P |
HR (95% CI) |
P |
HR (95% CI) |
P |
HR (95% CI) |
P | |
| FAP1 | ||||||||
| Low | 1 | 1 | 1 | 1 | ||||
| High | 0.42(0.24–0.74) | 0.003 | 0.75(0.45–1.25) | 0.266 | 0.99(0.65–1.49) | 0.954 | 0.84(0.54–1.31) | 0.452 |
| Gender | ||||||||
| Female | 1 | 1 | 1 | 1 | ||||
| Male | 2.3(1.37–3.85) | 0.002 | 1.84(1.18–2.84) | 0.007 | 1.48(0.98–2.23) | 0.063 | 1.3(0.79–2.12) | 0.302 |
| Histology | ||||||||
| SCC | 1 | 1 | 1 | 1 | ||||
| ADC | 3.13(1.91–5.16) | <0.001 | 2.25(1.45–3.48) | <0.001 | 1.16(0.78–1.73) | 0.451 | 1.11(0.72–1.71) | 0.647 |
| NOS | 1.92(0.76–4.88) | 0.170 | 2.24(1.12–4.48) | 0.022 | 0.96(0.51–1.8) | 0.894 | 0.56(0.24–1.27) | 0.166 |
| ECOG | ||||||||
| Normal | 1 | 1 | 1 | 1 | ||||
| Slightly reduced | 1.98(1.21–3.23) | 0.006 | 1.36(0.89–2.08) | 0.157 | 1.29(0.9–1.87) | 0.171 | 1.53(1.02–2.29) | 0.040 |
| In bed <50% | 2.92(1.11–7.65) | 0.029 | 1.86(0.83–4.2) | 0.133 | 1.36(0.62–2.99) | 0.447 | 1.08(0.41–2.82) | 0.880 |
| P-stage | ||||||||
| IA | 1 | 1 | 1 | 1 | ||||
| IB | 1.25(0.55–2.83) | 0.596 | 1.39(0.7–2.74) | 0.345 | 1.16(0.64–2.11) | 0.616 | 1.08(0.54–2.15) | 0.836 |
| IIA | 2.16(1.05–4.45) | 0.036 | 1.95(1.03–3.7) | 0.041 | 1.37(0.74–2.57) | 0.320 | 1.69(0.86–3.33) | 0.130 |
| IIB | 1.6(0.58–4.4) | 0.361 | 1.48(0.64–3.41) | 0.354 | 2.93(1.69–5.09) | <0.001 | 4.17(2.29–7.59) | <0.001 |
| IIIA | 5.3(2.49–11.28) | <0.001 | 4.36(2.28–8.3) | <0.001 | 4.2(2.34–7.53) | <0.001 | 6.68(3.43–12.98) | <0.001 |
| Vascular invasion | ||||||||
| No | 1 | 1 | 1 | 1 | ||||
| Yes | 2.84(1.61–5) | <0.001 | 2.14(1.34–3.44) | 0.002 | 1.57(1.03–2.41) | 0.037 | 1.67(1–2.78) | 0.048 |
| (E) CD8 High | (F) CD3 High | (G) CD8 Low | (H) CD3 Low | |||||
|
HR (95% CI) |
P |
HR (95% CI) |
P |
HR (95% CI) |
P |
HR (95% CI) |
P | |
| PDGFRβ | ||||||||
| Low | 1 | 1 | 1 | 1 | ||||
| High | 0.89(0.55–1.44) | 0.626 | 1.17(0.77–1.79) | 0.464 | 1.85(1.28–2.66) | <0.001 | 1.45(0.97–2.17) | 0.071 |
| Gender | ||||||||
| Female | 1 | 1 | ||||||
| Male | 2.19(1.29–3.74) | 0.004 | 1.8(1.15–2.8) | 0.010 | ||||
| Histology | ||||||||
| SCC | 1 | 1 | ||||||
| ADC | 2.84(1.73–4.67) | <0.001 | 2.22(1.42–3.46) | <0.001 | ||||
| NOS | 1.36(0.5–3.68) | 0.546 | 1.93(0.95–3.93) | 0.069 | ||||
| ECOG | ||||||||
| Normal | 1 | 1 | ||||||
| Slightly reduced | 1.88 (1.12–3.15) | 0.017 | 1.29(0.83–2.02) | 0.254 | ||||
| In bed <50% | 2.51 (0.97–6.52) | 0.059 | 1.76(0.77–4) | 0.179 | ||||
| P-stage | ||||||||
| IA | 1 | 1 | 1 | 1 | ||||
| IB | 1.33 (0.59–3.04) | 0.493 | 1.45 (0.73–2.89) | 0.292 | 1.17 (0.64–2.14) | 0.610 | 1.09 (0.55–2.2) | 0.798 |
| IIA | 2.36 (1.15–4.85) | 0.020 | 2.05 (1.08–3.91) | 0.029 | 1.42 (0.77–2.64) | 0.261 | 1.75 (0.9–3.43) | 0.102 |
| IIB | 1.92(0.69–5.31) | 0.212 | 1.67(0.72–3.87) | 0.228 | 2.91(1.67–5.05) | <0.001 | 3.92(2.12–7.26) | <0.001 |
| IIIA | 5.63(2.64–12.02) | <0.001 | 4.52(2.36–8.66) | <0.001 | 4.19(2.35–7.45) | <0.001 | 6.3(3.29–12.06) | <0.001 |
| Vascular invasion | ||||||||
| No | ||||||||
| Yes | 2.36(1.31–4.26) | 0.004 | 2.01(1.23–3.31) | 0.006 | 1.47(0.96–2.27) | 0.078 | 1.53(0.93–2.53) | 0.097 |
Abbreviations: FAP-1, Fibroblast activating protein 1; NSCLC, non small-cell lung cancer; CD8, cluster of differentiation 8; ECOG, Eastern Cooperative Oncology Group.